PIPERACILLIN/TAZOBACTAM KABI 4 g/0.5 g piperacillin (as sodium)/tazobactam (as sodium) 4 g/0.5 g powder for injection bottle

Ország: Ausztrália

Nyelv: angol

Forrás: Department of Health (Therapeutic Goods Administration)

Aktív összetevők:

tazobactam sodium, Quantity: 536.6 mg (Equivalent: tazobactam, Qty mg); piperacillin sodium, Quantity: 4.17 g (Equivalent: piperacillin, Qty g)

Beszerezhető a:

Fresenius Kabi Australia Pty Ltd

Gyógyszerészeti forma:

Injection, powder for

Összetétel:

Excipient Ingredients:

Az alkalmazás módja:

Intravenous

db csomag:

1, 5 & 10

Recept típusa:

(S4) Prescription Only Medicine

Terápiás javallatok:

Piperacillin/Tazobactam Kabi is indicated in the treatment of serious bacterial infections caused by susceptible strains of Beta-lactamase producing organisms in the conditions listed below: 1. Lower respiratory tract infections. 2. Urinary tract infections (complicated and uncomplicated). 3. Intra-abdominal infections. 4. Skin and skin structure infections. 5. Bacterial septicaemia. 6. Gynaecological infections.,,Children under the age of 12 years:,In hospitalised children aged 2 to 12 years, Piperacillin/Tazobactam Kabi Injection is indicated for the treatment of serious intra-abdominal infections. It has not been evaluated in this indication for paediatric patients below the age of 2 years.,While Piperacillin/Tazobactam Kabi Injection is indicated only for the conditions listed above, it may be used as a single agent in the treatment of mixed infections caused by piperacillin susceptible and Beta-lactamase producing piperacillin-resistant organisms. Appropriate culture and susceptibility tests should be performed before treatment in order to identify organisms causing infection to determine their susceptibilities to Piperacillin/Tazobactam. Therapy with Piperacillin/Tazobactam, however, may be initiated before results of such tests are known when there is a reason to believe the infection may involve any of the Beta-lactamase producing organisms listed above; however, once these results become available, appropriate therapy should be continued.,In serious infections, presumptive therapy with Piperacillin/Tazobactam Kabi may be initiated before susceptibility test results are available.,Combination therapy with Piperacillin/Tazobactam Kabi and aminoglycosides may be used in the treatment of serious infections caused by Pseudomonas aeruginosa. Both drugs should be used in full therapeutic doses. As soon as results of culture and susceptibility tests become available, antimicrobial therapy should be adjusted.

Termék összefoglaló:

Visual Identification: White to off white powder; Container Type: Bottle; Container Material: Glass Type II Clear; Container Life Time: 2 Years; Container Temperature: Store below 25 degrees Celsius

Engedélyezési státusz:

Registered

Engedély dátuma:

2019-12-20

Betegtájékoztató

Piperacillin/ Tazobactam Kabi Injection
1
PIPERACILLIN/ TAZOBACTAM KABI INJECTION
_ _
Piperacillin/ Tazobactam Kabi 2g/0.25g Injection & Piperacillin/
Tazobactam Kabi 4g/ 0.5 g Injection
CONSUMER MEDICINE INFORMATION
WHAT IS IN THIS LEAFLET
This leaflet answers some common
questions about Piperacillin/
Tazobactam Kabi Injection. It does not
contain all the available information. It
does not take the place of talking to
your doctor or pharmacist.
All medicines have risks and benefits.
Your doctor has weighed the risks of you
taking Piperacillin/ Tazobactam Kabi
Injection against the benefits this
medicine is expected to have for you.
IF YOU HAVE ANY QUESTIONS ABOUT
TAKING THIS MEDICINE, ASK YOUR
DOCTOR OR PHARMACIST.
KEEP THIS LEAFLET.
You may need to read it again. WHAT PIPERACILLIN/ TAZOBACTAM KABI INJECTION IS USED FOR
The name of your medicine is
Piperacillin/ Tazobactam Kabi Injection.
It contains the active ingredients
piperacillin and tazobactam. They
belong to a group of antibiotics called
penicillins that work by killing bacteria.
Piperacillin is an antibiotic that kills
many types of bacteria. Tazobactam
belongs in the penicillin group but does
not have activity against bacteria. It
helps piperacillin to overcome bacteria
which have become resistant to
piperacillin.
Piperacillin/ Tazobactam Kabi
Injection is active against bacteria
which cause serious infections
such as: -
•
Chest infections
•
Urine infections
•
Stomach infections
•
Skin infections
•
Gynaecological infections
•
Septicaemia (blood poisoning).
It is also used to treat many other
infections.
In hospitalised children aged 2 to 12
years, Piperacillin/ Tazobactam Kabi
Injection is used to treat serious
infections in the abdomen. Piperacillin/
Tazobactam Kabi Injection is not
recommended to treat abdominal
infections in children under 2 years.
Piperacillin/Tazobactam Kabi Injection
will not work against infections caused
by viruses such as colds or flu.
This medicine is available only with a
doctor's prescription.
Piperacillin/ Tazo

Termékjellemzők

Australian PI
1
AUSTRALIAN PRODUCT INFORMATION – PIPERACILLIN/TAZOBACTAM KABI (PIPERACILLIN/TAZOBACTAM)
POWDER FOR INJECTION
1
NAME OF THE MEDICINE
Piperacillin sodium / Tazobactam sodium
2
QUALITATIVE AND QUANTITATIVE COMPOSITION
Each 2 g/0.25 g single dose vial contains piperacillin sodium
equivalent to 2 grams of
piperacillin and tazobactam sodium equivalent to 250 mg of tazobactam.
Each 4 g/0.5 g single dose vial contains piperacillin sodium
equivalent to 4 grams of
piperacillin and tazobactam sodium equivalent to 500 mg of tazobactam.
There are no excipients.
3
PHARMACEUTICAL FORM
Piperacillin/Tazobactam is a white to off white powder for solution
for infusion.
4 CLINICAL PARTICULARS
4.1
T
HERAPEUTIC INDICATIONS
Piperacillin/Tazobactam Kabi is indicated in the treatment of serious
bacterial infections
caused by susceptible strains of β-lactamase producing organisms in
the conditions listed
below:
1. Lower respiratory tract infections
2. Urinary tract infections (complicated and uncomplicated)
3. Intra-abdominal infections
4. Skin and skin structure infections
5. Bacterial septicaemia
6. Gynaecological infections
Children under the age of 12 years
In hospitalised children aged 2 to 12 years, Piperacillin/Tazobactam
Kabi Injection is indicated
for the treatment of serious intra-abdominal infections. It has not
been evaluated in this
indication for paediatric patients below the age of 2 years.
Australian PI
2
While Piperacillin/Tazobactam Kabi Injection is indicated only for the
conditions listed above,
it may be used as a single agent in the treatment of mixed infections
caused by piperacillin
susceptible and β-lactamase producing, piperacillin-resistant
organisms. Appropriate culture
and susceptibility tests should be performed before treatment in order
to identify organisms
causing infection to determine their susceptibilities to
Piperacillin/Tazobactam
. Therapy with
Piperacillin/Tazobactam
, however, may be initiated before results of such tests are known
when there is reason to believe the infection m